,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2007', 'fs': 'Sep 2007', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFe2AL'}, 'Id': 'a0POZ00000FSvFe2AL', 'Event_Date__c': '2007-09-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Sep 2007', 'Status_History__c': 'a132P000000ApDUQA0'}, 'change': None}]",Sep 2007,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2007', 'fs': 'Sep 2007', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFf2AL'}, 'Id': 'a0POZ00000FSvFf2AL', 'Event_Date__c': '2007-09-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2007', 'Status_History__c': 'a132P000000ApDaQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2007-11.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2007-11.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2007', 'fs': 'Nov 2007', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 7 November 2007.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 7 November 2007.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFg2AL'}, 'Id': 'a0POZ00000FSvFg2AL', 'Event_Date__c': '2007-11-07', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 7 November 2007.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2007-11.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Nov 2007', 'Status_History__c': 'a132P000000ApF4QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2010', 'fs': 'Aug 2010', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFh2AL'}, 'Id': 'a0POZ00000FSvFh2AL', 'Event_Date__c': '2010-08-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2010', 'Status_History__c': 'a132P000000Apd7QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2010', 'fs': 'Aug 2010', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFi2AL'}, 'Id': 'a0POZ00000FSvFi2AL', 'Event_Date__c': '2010-08-17', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2010', 'Status_History__c': 'a132P000000ApePQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-11.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-11.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2010', 'fs': 'Nov 2010', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFj2AL'}, 'Id': 'a0POZ00000FSvFj2AL', 'Event_Date__c': '2010-11-04', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-11.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Nov 2010', 'Status_History__c': 'a132P000000ApgoQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2011', 'fs': 'May 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFk2AL'}, 'Id': 'a0POZ00000FSvFk2AL', 'Event_Date__c': '2011-05-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2011', 'Status_History__c': 'a132P000000ApoiQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2011', 'fs': 'Aug 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFl2AL'}, 'Id': 'a0POZ00000FSvFl2AL', 'Event_Date__c': '2011-08-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Aug 2011', 'Status_History__c': 'a132P000000ApsWQAS'}, 'change': None}, {'Summary': {'s': 'The subcommittee agreed with PTAC&#39;s recommendation to decline this application.', 'fs': 'The subcommittee agreed with PTAC&#39;s recommendation to decline this application.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 24 May 2013.', 'fs': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 24 May 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFm2AL'}, 'Id': 'a0POZ00000FSvFm2AL', 'Event_Date__c': '2013-05-24', 'Event_Description__c': 'Clinical advice received from Respiratory Subcommittee at meeting Friday 24 May 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf"" target=""_blank"">Respiratory Subcommittee minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The subcommittee agreed with PTAC&#39;s recommendation to decline this application.', 'Formatted_Date__c': 'May 2013', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000AqPcQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2013', 'fs': 'Aug 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFo2AL'}, 'Id': 'a0POZ00000FSvFo2AL', 'Event_Date__c': '2013-08-30', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Aug 2013', 'Status_History__c': 'a132P000000AqSYQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFs2AL'}, 'Id': 'a0POZ00000FSvFs2AL', 'Event_Date__c': '2020-09-24', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 November 2010.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000CCDcQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2020', 'fs': 'Oct 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Respiratory Subcommittee meeting to provide advice on Wednesday 28 October 2020', 'fs': 'Assigned to Respiratory Subcommittee meeting to provide advice on Wednesday 28 October 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFt2AL'}, 'Id': 'a0POZ00000FSvFt2AL', 'Event_Date__c': '2020-10-19', 'Event_Description__c': 'Assigned to Respiratory Subcommittee meeting to provide advice on Wednesday 28 October 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2020', 'Status_History__c': 'a132P000000CMoyQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2020', 'fs': 'Dec 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Respiratory Subcommittee meeting to provide advice on Wednesday 28 October 2020', 'fs': 'Assigned to Respiratory Subcommittee meeting to provide advice on Wednesday 28 October 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFu2AL'}, 'Id': 'a0POZ00000FSvFu2AL', 'Event_Date__c': '2020-12-03', 'Event_Description__c': 'Assigned to Respiratory Subcommittee meeting to provide advice on Wednesday 28 October 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2020', 'Status_History__c': 'a132P000000CPTLQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <strong>recommended</strong> that fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200) be funded for the treatment of severe asthma with a <strong>medium priority</strong> within the context of respiratory disease, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 11px;"">Initial application</strong><span style=""font-size: 11px;""> – (severe asthma) from any relevant practitioner on the recommendation of a paediatrician or respiratory physician. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">1.\xa0\xa0\xa0\xa0Despite adherence to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever plus maintenance regimen including previous trials of appropriate meds, the patient has experienced an asthma exacerbation in the previous 6 months that required oral corticosteroids; and</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">2.\xa0\xa0\xa0\xa0Conditions that mimic asthma (e.g., vocal cord dysfunction, central airway obstruction etc.) have been excluded or managed.</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 11px;"">Renewal </strong><span style=""font-size: 11px;"">– (severe asthma) from any relevant practitioner on the recommendation of a paediatrician or respiratory physician. Approvals valid without further renewal where the treatment remains appropriate and the patient continues to benefit from treatment</span></p><p class=""ql-indent-1""><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered the health need of this patient group with severe disease, the potential benefits of fluticasone furoate/vilanterol 200/25 mcg, and the risks associated with use of high dose inhaled corticosteroids in this patient group.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <strong>recommended</strong> that fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200) be funded for the treatment of severe asthma with a <strong>medium priority</strong> within the context of respiratory disease, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 11px;"">Initial application</strong><span style=""font-size: 11px;""> – (severe asthma) from any relevant practitioner on the recommendation of a paediatrician or respiratory physician. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">1.\xa0\xa0\xa0\xa0Despite adherence to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever plus maintenance regimen including previous trials of appropriate meds, the patient has experienced an asthma exacerbation in the previous 6 months that required oral corticosteroids; and</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">2.\xa0\xa0\xa0\xa0Conditions that mimic asthma (e.g., vocal cord dysfunction, central airway obstruction etc.) have been excluded or managed.</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 11px;"">Renewal </strong><span style=""font-size: 11px;"">– (severe asthma) from any relevant practitioner on the recommendation of a paediatrician or respiratory physician. Approvals valid without further renewal where the treatment remains appropriate and the patient continues to benefit from treatment</span></p><p class=""ql-indent-1""><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered the health need of this patient group with severe disease, the potential benefits of fluticasone furoate/vilanterol 200/25 mcg, and the risks associated with use of high dose inhaled corticosteroids in this patient group.</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a quarter of patients with asthma of any severity cannot adequately control their asthma with currently funded inhaler therapy at standard doses. The Subcommittee considered that patients with severe uncontrolled asthma can be very unwell, experiencing shortness of breath and requiring hospital stays for management, all of which impacts on the families/whānau of people with severe uncontrolled asthma. The Subcommittee noted that Māori and Pacific people are disproportionately affected by asthma, have more than two times the mortality rate as non-Māori and are more likely to be hospitalised due to severe asthma (<a href=""https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-mana-hauora-tutohu-health-status-indicators/respiratory-disease"" target=""_blank"">Ministry of Health, 2013/14 New Zealand Health Survey and National Minimum Data Set [NMDS]</a>).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that approximately 25% of patients with severe asthma are uncontrolled and considered that about 5-10% patients with severe, uncontrolled asthma despite all other options (e.g. optimisation of current treatments through asthma nurse support; a trial of high-dose inhaled corticosteroids) may be eligible to commence a biologic treatment with a monoclonal antibody i.e. mepolizumab or omalizumab. The Subcommittee considered that actual uptake of these biologics is only about 2% of patients with severe, uncontrolled asthma despite all other options due to patient preference for inhaled over biological therapy as well as the logistical complexity of biological therapy. The Subcommittee noted that mepolizumab and omalizumab are given as an injection and require admission to a day stay unit (at a cost of $500 per admission) for at least the first few treatments; subsequent doses of omalizumab may be given in the community via prefilled syringes, and mepolizumab is expected to be able to be delivered in the community after Medsafe approval in 2021.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the Special Authority criteria for mepolizumab and omalizumab each require a patient to have trialled high-dose oral corticosteroids (1000 mcg per day or equivalent) with a long-acting beta agonist (LABA); current funded options are such that this high dose of steroid cannot be achieved without using two separate devices. The Subcommittee noted that a proportion of patients who trial higher doses of an inhaled corticosteroid may benefit from anti-inflammatory reliever therapy with maintenance (<a href=""https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(19)31948-8"" target=""_blank"">Hardy et al. Lancet. 2019;394:919-28</a>).</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for fluticasone propionate (FP) with salmeterol (Sal) (high dose) was considered by PTAC and recommended for decline in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2007-11.pdf"" target=""_blank"">November 2007</a>, <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-11.pdf"" target=""_blank"">November 2010</a> and in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf"" target=""_blank"">August 2011</a>. In <a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf"" target=""_blank"">May 2013</a>, the Respiratory Subcommittee had reviewed and agreed with PTAC’s recommendation to decline the application. Overall, the rationale for the recommendation to decline was concern about the high dose of corticosteroid in the combination product, which could cause significant side effects (e.g. pneumonia) and it was noted that high-dose inhaled steroid regimens could be achieved by combining existing funded inhalers (e.g. an inhaled corticosteroid [ICS]/ long-acting beta agonist [LABA] plus an ICS).</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application was included in PHARMAC’s <a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">December 2019</a> consultation proposing to decline inactive funding applications and that a responder had noted that the Special Authority for omalizumab requires that patients be adherent to an inhaled corticosteroid dose equivalent to 1000 mcg FP per day or equivalent (where currently, this threshold cannot be reached without prescribing two separate inhalers, one containing the combination FP/Sal and another containing FP only; the responder considered that having FP/Sal (high dose) available would resolve the need for two inhalers to satisfy this Special Authority criterion for this population). The Subcommittee noted that no further evidence has been provided regarding FP/Sal (high dose), and considered that a daily dose of 1600 mcg budesonide would also satisfy the Special Authority requirement for omalizumab.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient population who require high dose inhaled corticosteroids, or biologics, for severe asthma are a high need group with impaired quality of life and an increased risk of death, experiencing multiple exacerbations per year and often requiring hospital admission to manage their disease. The Subcommittee considered that these patients could benefit from a move to one high-dose inhaler, which could reduce the risk of critical errors associated with use of multiple devices</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the unmet need of patients with severe asthma that was identified by the consultation respondent regarding FP/Sal (high dose) could be addressed by amending the Special Authority criteria for mepolizumab and omalizumab to state that a patient had trialled a medium or high dose of high-potency inhaled corticosteroid according to the relevant treatment guidelines, as an alternative to specifying a particular dose. The Subcommittee however considered that adjusting the criteria for high dose corticosteroids would likely increase the number of patients eligible for biological treatment</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a quarter of patients with asthma of any severity cannot adequately control their asthma with currently funded inhaler therapy at standard doses. The Subcommittee considered that patients with severe uncontrolled asthma can be very unwell, experiencing shortness of breath and requiring hospital stays for management, all of which impacts on the families/whānau of people with severe uncontrolled asthma. The Subcommittee noted that Māori and Pacific people are disproportionately affected by asthma, have more than two times the mortality rate as non-Māori and are more likely to be hospitalised due to severe asthma (<a href=""https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-mana-hauora-tutohu-health-status-indicators/respiratory-disease"" target=""_blank"">Ministry of Health, 2013/14 New Zealand Health Survey and National Minimum Data Set [NMDS]</a>).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that approximately 25% of patients with severe asthma are uncontrolled and considered that about 5-10% patients with severe, uncontrolled asthma despite all other options (e.g. optimisation of current treatments through asthma nurse support; a trial of high-dose inhaled corticosteroids) may be eligible to commence a biologic treatment with a monoclonal antibody i.e. mepolizumab or omalizumab. The Subcommittee considered that actual uptake of these biologics is only about 2% of patients with severe, uncontrolled asthma despite all other options due to patient preference for inhaled over biological therapy as well as the logistical complexity of biological therapy. The Subcommittee noted that mepolizumab and omalizumab are given as an injection and require admission to a day stay unit (at a cost of $500 per admission) for at least the first few treatments; subsequent doses of omalizumab may be given in the community via prefilled syringes, and mepolizumab is expected to be able to be delivered in the community after Medsafe approval in 2021.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the Special Authority criteria for mepolizumab and omalizumab each require a patient to have trialled high-dose oral corticosteroids (1000 mcg per day or equivalent) with a long-acting beta agonist (LABA); current funded options are such that this high dose of steroid cannot be achieved without using two separate devices. The Subcommittee noted that a proportion of patients who trial higher doses of an inhaled corticosteroid may benefit from anti-inflammatory reliever therapy with maintenance (<a href=""https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(19)31948-8"" target=""_blank"">Hardy et al. Lancet. 2019;394:919-28</a>).</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for fluticasone propionate (FP) with salmeterol (Sal) (high dose) was considered by PTAC and recommended for decline in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2007-11.pdf"" target=""_blank"">November 2007</a>, <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-11.pdf"" target=""_blank"">November 2010</a> and in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf"" target=""_blank"">August 2011</a>. In <a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf"" target=""_blank"">May 2013</a>, the Respiratory Subcommittee had reviewed and agreed with PTAC’s recommendation to decline the application. Overall, the rationale for the recommendation to decline was concern about the high dose of corticosteroid in the combination product, which could cause significant side effects (e.g. pneumonia) and it was noted that high-dose inhaled steroid regimens could be achieved by combining existing funded inhalers (e.g. an inhaled corticosteroid [ICS]/ long-acting beta agonist [LABA] plus an ICS).</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application was included in PHARMAC’s <a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">December 2019</a> consultation proposing to decline inactive funding applications and that a responder had noted that the Special Authority for omalizumab requires that patients be adherent to an inhaled corticosteroid dose equivalent to 1000 mcg FP per day or equivalent (where currently, this threshold cannot be reached without prescribing two separate inhalers, one containing the combination FP/Sal and another containing FP only; the responder considered that having FP/Sal (high dose) available would resolve the need for two inhalers to satisfy this Special Authority criterion for this population). The Subcommittee noted that no further evidence has been provided regarding FP/Sal (high dose), and considered that a daily dose of 1600 mcg budesonide would also satisfy the Special Authority requirement for omalizumab.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient population who require high dose inhaled corticosteroids, or biologics, for severe asthma are a high need group with impaired quality of life and an increased risk of death, experiencing multiple exacerbations per year and often requiring hospital admission to manage their disease. The Subcommittee considered that these patients could benefit from a move to one high-dose inhaler, which could reduce the risk of critical errors associated with use of multiple devices</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the unmet need of patients with severe asthma that was identified by the consultation respondent regarding FP/Sal (high dose) could be addressed by amending the Special Authority criteria for mepolizumab and omalizumab to state that a patient had trialled a medium or high dose of high-potency inhaled corticosteroid according to the relevant treatment guidelines, as an alternative to specifying a particular dose. The Subcommittee however considered that adjusting the criteria for high dose corticosteroids would likely increase the number of patients eligible for biological treatment</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200).</p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the consultation feedback received regarding fluticasone propionate with salmeterol (high dose) for severe asthma when this had been proposed for decline.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200).</p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the consultation feedback received regarding fluticasone propionate with salmeterol (high dose) for severe asthma when this had been proposed for decline.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regard to item 9 and the Respiratory Subcommittee’s consideration of fluticasone furoate/vilanterol 200/25 mcg for patients with severe asthma:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the recommendation to fund fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200) for the treatment of severe asthma with a medium priority within the context of respiratory disease.</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed concerns regarding the proposed Special Authority criteria for access to fluticasone furoate/vilanterol 200/25 mcg. The Subcommittee considered that there may be a risk of slippage for this potentially large patient group. In addition, the Committee noted the potential risk of pneumonia associated with the use of high dose inhaled corticosteroids. The Committee noted that most asthma exacerbations would be managed in the community and considered there to be a risk of overprescribing.\xa0</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it would like to review the application to further consider the wider issues of this high dose inhaled corticosteroid. The Committee considered that its primary concern regarded the targeting of the most appropriate patient population. The Committee considered that it would be useful to review if available NZ-specific evidence for adverse events and the risk of slippage for high dose inhaled corticosteroids.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regard to item 9 and the Respiratory Subcommittee’s consideration of fluticasone furoate/vilanterol 200/25 mcg for patients with severe asthma:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the recommendation to fund fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200) for the treatment of severe asthma with a medium priority within the context of respiratory disease.</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed concerns regarding the proposed Special Authority criteria for access to fluticasone furoate/vilanterol 200/25 mcg. The Subcommittee considered that there may be a risk of slippage for this potentially large patient group. In addition, the Committee noted the potential risk of pneumonia associated with the use of high dose inhaled corticosteroids. The Committee noted that most asthma exacerbations would be managed in the community and considered there to be a risk of overprescribing.\xa0</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it would like to review the application to further consider the wider issues of this high dose inhaled corticosteroid. The Committee considered that its primary concern regarded the targeting of the most appropriate patient population. The Committee considered that it would be useful to review if available NZ-specific evidence for adverse events and the risk of slippage for high dose inhaled corticosteroids.</p>', 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 28 October 2020.', 'fs': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 28 October 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFv2AL'}, 'Id': 'a0POZ00000FSvFv2AL', 'Event_Date__c': '2021-03-12', 'Event_Description__c': 'Clinical advice received from Respiratory Subcommittee at meeting Wednesday 28 October 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'Mar 2021', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <strong>recommended</strong> that fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200) be funded for the treatment of severe asthma with a <strong>medium priority</strong> within the context of respiratory disease, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 11px;"">Initial application</strong><span style=""font-size: 11px;""> – (severe asthma) from any relevant practitioner on the recommendation of a paediatrician or respiratory physician. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">Both:</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">1.\xa0\xa0\xa0\xa0Despite adherence to optimised asthma therapy including inhaled corticosteroids (equivalent to at least 1000 mcg per day of fluticasone propionate) plus long acting beta-2 agonist, or budesonide/formoterol as part of the anti-inflammatory reliever plus maintenance regimen including previous trials of appropriate meds, the patient has experienced an asthma exacerbation in the previous 6 months that required oral corticosteroids; and</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">2.\xa0\xa0\xa0\xa0Conditions that mimic asthma (e.g., vocal cord dysfunction, central airway obstruction etc.) have been excluded or managed.</span></p><p class=""ql-indent-1""><span style=""color: rgb(8, 7, 7); font-size: 11px;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""font-size: 11px;"">Renewal </strong><span style=""font-size: 11px;"">– (severe asthma) from any relevant practitioner on the recommendation of a paediatrician or respiratory physician. Approvals valid without further renewal where the treatment remains appropriate and the patient continues to benefit from treatment</span></p><p class=""ql-indent-1""><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered the health need of this patient group with severe disease, the potential benefits of fluticasone furoate/vilanterol 200/25 mcg, and the risks associated with use of high dose inhaled corticosteroids in this patient group.</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200).</p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the consultation feedback received regarding fluticasone propionate with salmeterol (high dose) for severe asthma when this had been proposed for decline.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a quarter of patients with asthma of any severity cannot adequately control their asthma with currently funded inhaler therapy at standard doses. The Subcommittee considered that patients with severe uncontrolled asthma can be very unwell, experiencing shortness of breath and requiring hospital stays for management, all of which impacts on the families/whānau of people with severe uncontrolled asthma. The Subcommittee noted that Māori and Pacific people are disproportionately affected by asthma, have more than two times the mortality rate as non-Māori and are more likely to be hospitalised due to severe asthma (<a href=""https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-mana-hauora-tutohu-health-status-indicators/respiratory-disease"" target=""_blank"">Ministry of Health, 2013/14 New Zealand Health Survey and National Minimum Data Set [NMDS]</a>).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that approximately 25% of patients with severe asthma are uncontrolled and considered that about 5-10% patients with severe, uncontrolled asthma despite all other options (e.g. optimisation of current treatments through asthma nurse support; a trial of high-dose inhaled corticosteroids) may be eligible to commence a biologic treatment with a monoclonal antibody i.e. mepolizumab or omalizumab. The Subcommittee considered that actual uptake of these biologics is only about 2% of patients with severe, uncontrolled asthma despite all other options due to patient preference for inhaled over biological therapy as well as the logistical complexity of biological therapy. The Subcommittee noted that mepolizumab and omalizumab are given as an injection and require admission to a day stay unit (at a cost of $500 per admission) for at least the first few treatments; subsequent doses of omalizumab may be given in the community via prefilled syringes, and mepolizumab is expected to be able to be delivered in the community after Medsafe approval in 2021.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the Special Authority criteria for mepolizumab and omalizumab each require a patient to have trialled high-dose oral corticosteroids (1000 mcg per day or equivalent) with a long-acting beta agonist (LABA); current funded options are such that this high dose of steroid cannot be achieved without using two separate devices. The Subcommittee noted that a proportion of patients who trial higher doses of an inhaled corticosteroid may benefit from anti-inflammatory reliever therapy with maintenance (<a href=""https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(19)31948-8"" target=""_blank"">Hardy et al. Lancet. 2019;394:919-28</a>).</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for fluticasone propionate (FP) with salmeterol (Sal) (high dose) was considered by PTAC and recommended for decline in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2007-11.pdf"" target=""_blank"">November 2007</a>, <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2010-11.pdf"" target=""_blank"">November 2010</a> and in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-08.pdf"" target=""_blank"">August 2011</a>. In <a href=""https://www.pharmac.govt.nz/assets/ptac-respiratory-subcommittee-minutes-2013-05-24.pdf"" target=""_blank"">May 2013</a>, the Respiratory Subcommittee had reviewed and agreed with PTAC’s recommendation to decline the application. Overall, the rationale for the recommendation to decline was concern about the high dose of corticosteroid in the combination product, which could cause significant side effects (e.g. pneumonia) and it was noted that high-dose inhaled steroid regimens could be achieved by combining existing funded inhalers (e.g. an inhaled corticosteroid [ICS]/ long-acting beta agonist [LABA] plus an ICS).</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application was included in PHARMAC’s <a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">December 2019</a> consultation proposing to decline inactive funding applications and that a responder had noted that the Special Authority for omalizumab requires that patients be adherent to an inhaled corticosteroid dose equivalent to 1000 mcg FP per day or equivalent (where currently, this threshold cannot be reached without prescribing two separate inhalers, one containing the combination FP/Sal and another containing FP only; the responder considered that having FP/Sal (high dose) available would resolve the need for two inhalers to satisfy this Special Authority criterion for this population). The Subcommittee noted that no further evidence has been provided regarding FP/Sal (high dose), and considered that a daily dose of 1600 mcg budesonide would also satisfy the Special Authority requirement for omalizumab.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient population who require high dose inhaled corticosteroids, or biologics, for severe asthma are a high need group with impaired quality of life and an increased risk of death, experiencing multiple exacerbations per year and often requiring hospital admission to manage their disease. The Subcommittee considered that these patients could benefit from a move to one high-dose inhaler, which could reduce the risk of critical errors associated with use of multiple devices</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the unmet need of patients with severe asthma that was identified by the consultation respondent regarding FP/Sal (high dose) could be addressed by amending the Special Authority criteria for mepolizumab and omalizumab to state that a patient had trialled a medium or high dose of high-potency inhaled corticosteroid according to the relevant treatment guidelines, as an alternative to specifying a particular dose. The Subcommittee however considered that adjusting the criteria for high dose corticosteroids would likely increase the number of patients eligible for biological treatment</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regard to item 9 and the Respiratory Subcommittee’s consideration of fluticasone furoate/vilanterol 200/25 mcg for patients with severe asthma:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the recommendation to fund fluticasone furoate/vilanterol 200/25 mcg (Breo Ellipta 200) for the treatment of severe asthma with a medium priority within the context of respiratory disease.</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed concerns regarding the proposed Special Authority criteria for access to fluticasone furoate/vilanterol 200/25 mcg. The Subcommittee considered that there may be a risk of slippage for this potentially large patient group. In addition, the Committee noted the potential risk of pneumonia associated with the use of high dose inhaled corticosteroids. The Committee noted that most asthma exacerbations would be managed in the community and considered there to be a risk of overprescribing.\xa0</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it would like to review the application to further consider the wider issues of this high dose inhaled corticosteroid. The Committee considered that its primary concern regarded the targeting of the most appropriate patient population. The Committee considered that it would be useful to review if available NZ-specific evidence for adverse events and the risk of slippage for high dose inhaled corticosteroids.</p>', 'Status_History__c': 'a132P000000Cg80QAC'}, 'change': None}]",Sep 2007,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2013', 'fs': 'Aug 2013', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFn2AL'}, 'Id': 'a0POZ00000FSvFn2AL', 'Event_Date__c': '2013-08-28', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Aug 2013', 'Status_History__c': 'a132P000000BEisQAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFw2AL'}, 'Id': 'a0POZ00000FSvFw2AL', 'Event_Date__c': '2021-03-28', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CigeQAC'}, 'change': None}]",Aug 2013,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFp2AL'}, 'Id': 'a0POZ00000FSvFp2AL', 'Event_Date__c': '2013-11-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqWSQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFx2AL'}, 'Id': 'a0POZ00000FSvFx2AL', 'Event_Date__c': '2023-09-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000001vnv1YAA'}, 'change': None}]",Nov 2013,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p>The consultation can be found here:</p><p><a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/</a></p>', 'fs': '<p>The consultation can be found here:</p><p><a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2019', 'fs': 'Dec 2019', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFq2AL'}, 'Id': 'a0POZ00000FSvFq2AL', 'Event_Date__c': '2019-12-17', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p>The consultation can be found here:</p><p><a href=""https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/"" target=""_blank"">https://www.pharmac.govt.nz/news/proposal-to-decline-inactive-funding-applications/</a></p>', 'Formatted_Date__c': 'Dec 2019', 'Status_History__c': 'a132P000000BeSNQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFy2AL'}, 'Id': 'a0POZ00000FSvFy2AL', 'Event_Date__c': '2024-10-17', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-decline-inactive-applications-oct24"" target=""_blank"">Consultation</a></p>', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000FUjf2YAD'}, 'change': None}]",Dec 2019,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFr2AL'}, 'Id': 'a0POZ00000FSvFr2AL', 'Event_Date__c': '2020-01-31', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Jan 2020', 'Status_History__c': 'a132P000000BeSSQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000FSvFz2AL'}, 'Id': 'a0POZ00000FSvFz2AL', 'Event_Date__c': '2024-11-30', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000HCsSgYAL'}, 'change': None}]",Jan 2020,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
